title: Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness.
abstract: Patients with severe mental illnesses, such as schizophrenia and bipolar disorder, are at increased risk of developing metabolic disorders including obesity, diabetes, and dyslipidemia. All of these comorbidities increase the risk of cardiovascular disease and mortality. Different approaches, including diet and lifestyle modifications, behavioral therapy and switching antipsychotic agents, have been proposed to manage these metabolic abnormalities. However, these interventions may be insufficient, impractical or fail to counteract the metabolic dysregulation. Consequently, a variety of pharmacological agents such as antidiabetic drugs, have been studied in an attempt to reverse the weight gain and metabolic abnormalities evident in these patients. Despite a significant effect, many of these treatments are used off-label. This qualitative review focuses on pharmacological agents that could offer significant benefits in the management of cardio-metabolic disorders associated with serious mental illness.
authors.forename: Youssef
authors.initials: Y
authors.lastname: Kouidrat
authors.forename: Ali
authors.initials: A
authors.lastname: Amad
authors.affiliation: University Psychiatric Centre, Catholic University Louvain, Leuvensesteenweg 517, 3070 Kortenberg, Belgium. marc.de.hert@uc-kortenberg.be.
authors.forename: Marc
authors.initials: M
authors.lastname: De Hert
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D057970:Inappropriate Prescribing; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D056687:Off-Label Use; D061214:Patient Safety; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D019440:Anti-Obesity Agents; D014150:Antipsychotic Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents